Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1B | P35368 | 1/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | TOP2A | P11388 | 2/20 | 0.60 |
| ▸ | BACE1 | P56817 | 6/20 | 0.56 |
| ▸ | BACE2 | Q9Y5Z0 | 6/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.54 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.54 |
| ▸ | SALL4 | Q9UJQ4 | 2/20 | 0.53 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL997742 | 0.87 | GAA (0.59) | ADRA1BKDM4EGAAMAPK1TOP2A | |
| SCHEMBL25414843 | 0.86 | ADRA1B (1.00) | ADRA1BKDM4ETOP2ABACE1BACE2 | |
| SCHEMBL25416714 | 0.85 | ADRA1B (0.91) | ADRA1BKDM4ETOP2ABACE1BACE2 | |
| SCHEMBL6650055 | 0.84 | GAA (0.67) | ADRA1BKDM4EGAAMAPK1BACE1 | |
| SCHEMBL6651229 | 0.82 | GAA (0.71) | ADRA1BKDM4EGAAMAPK1TOP2A | |
| SCHEMBL12781599 | 0.82 | ADRA1B (0.71) | ADRA1BKDM4EGAAMAPK1TOP2A | |
| SCHEMBL6644372 | 0.81 | BRD4 (0.58) | ADRA1BKDM4EGAAMAPK1BRD4 | |
| SCHEMBL16424708 | 0.79 | ADRA1B (0.80) | ADRA1BKDM4ETOP2ABACE1BACE2 | |
| SCHEMBL28600538 | 0.79 | ADRA1B (0.80) | ADRA1BKDM4ETOP2ABACE1BACE2 | |
| SCHEMBL6643374 | 0.79 | ADRA1B (0.74) | ADRA1BTOP2ABACE1BACE2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1218382-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-01-28 | — | — | EP | claimed |
| US-6638933-B2 | Analgesics | GRUENENTHAL GMBH (DE) | 2003-10-28 | — | — | US | claimed |
| JP-2003511451-A | — | — | 2003-03-25 | — | — | JP | claimed |
| US-20030018032-A1 | Bicyclic imidazo-3-yl-amine derivatives | GRUENENTHAL GMBH | 2003-01-23 | — | — | US | claimed |
| EP-1218382-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | claimed |
| WO-2001027111-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | claimed |
| WO-2007105023-A1 | MODULATION OF PHOSPHORYL TRANSFERASE ACTIVITY OF GLUTAMINE SYNTHETASE | CSIR (ZA) | 2007-09-20 | — | — | WO | disclosed |
| EP-1218382-B1 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2004-01-28 | — | — | EP | disclosed |
| US-6638933-B2 | Analgesics | GRUENENTHAL GMBH (DE) | 2003-10-28 | — | — | US | disclosed |
| US-20030018032-A1 | Bicyclic imidazo-3-yl-amine derivatives | GRUENENTHAL GMBH | 2003-01-23 | — | — | US | disclosed |
| EP-1218382-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001027111-A2 | BICYCLIC IMIDAZO-3-YL-AMINE DERIVATIVES | Grünenthal GmbH (DE) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018032-A1 | Bicyclic imidazo-3-yl-amine derivatives | OPRK1, IPO4, GRIN3A | ADRA1B 477/4885KDM4E 2957/4885GAA 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.